Profound Medical Corp (PROF) Stock Forecast & Price Target
Profound Medical Corp · NASDAQ
$7.27-0.06 (-0.82%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Profound Medical Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 65% above the current $7.27. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.24 next quarter toward $-0.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Profound Medical Corp.
As of Jul, 1 of 1 firms rate PROF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PROF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.26 – $-0.23 · 4 analysts · -7% YoY
Next period, 4 analysts expect Profound Medical Corp to earn $-0.24 a share (range $-0.26 – $-0.23), versus $-0.26 a year earlier. Full-year consensus is $-0.84, growing to $-0.75 the year after.
REVENUE · NEXT QUARTER
$9.0M
Range $8.1M – $10.3M · 4 analysts · +21% YoY
Revenue is expected to reach $9.0M (range $8.1M – $10.3M), +21.3% year-over-year. Full-year consensus is $36.0M, rising to $61.1M next year.
Top analysts covering Profound Medical Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PROF.
#1
BH
Benjamin Haynor
Lake Street
Buy
$12.00+65.1% to target
Coverage
—
+ Follow
#2
MF
Michael Freeman
Raymond James
Buy
$11.00+51.3% to target
Coverage
—
+ Follow
PROF stock forecast FAQ
What is PROF's average 12-month price target?+
The 1 analysts with a live target average $12.00 for Profound Medical Corp over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is PROF stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PROF?+
1 analysts have an active rating on Profound Medical Corp, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PROF?+
Among analysts who currently cover PROF, Benjamin Haynor of Lake Street has the strongest overall Quantellect track record. Their current call is Buy with a $12.00 target.
What is Profound Medical Corp's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.26 – $-0.23) across 4 analysts. Full-year EPS is projected at $-0.84, rising to $-0.75 the following year.
How much revenue is Profound Medical Corp expected to report next quarter?+
Consensus revenue is $9.0M (range $8.1M – $10.3M). Full-year revenue is projected at $36.0M, growing to $61.1M next year.
Have analysts been upgrading or downgrading PROF lately?+
As of Jul, 1 of 1 firms rate PROF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PROF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
